• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Rational selection of an ideal oncolytic virus to address current limitations in clinical translation
Int Rev Cell Mol Biol. 2023;379:241-261. doi: 10.1016/bs.ircmb.2023.03.004. Epub 2023 Apr 1.ABSTRACTOncolytic virus therapy (OVT) is a promising modality that leverages the propensity of natural or engineered viruses to selectively replicate in and kill cancer cells. Over the past decade, (pre)clinical studies have focused on the development and testing of adenovirus, herpes simplex virus, and vaccinia virus-based vectors. These studies have identified barriers to success confronting the field. Here, we propose a set of selection criteria or ideal properties of a successful oncolytic virus, which include lack of pathogenic...
Source: Mol Biol Cell - August 4, 2023 Category: Molecular Biology Authors: Rupsa Basu Chad M Moles Source Type: research

Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success
Int Rev Cell Mol Biol. 2023;379:169-188. doi: 10.1016/bs.ircmb.2023.04.001. Epub 2023 Apr 26.ABSTRACTHigh-grade gliomas (HGGs) are the most common and aggressive primary brain tumors in both adult and pediatric populations. Despite the multimodal treatment modality currently available for HGG, the prognosis is dismal, with a low overall survival rate at two years after diagnosis. In the last decade, oncolytic virotherapy has emerged as a promising and feasible therapeutic tool in management of these tumors due to its oncolytic and immunostimulatory properties. Various oncolytic viruses, such as herpes simplex virus, adenov...
Source: Mol Biol Cell - August 4, 2023 Category: Molecular Biology Authors: Irati Herv ás-Corpión Marta M Alonso Source Type: research

Viral vectors engineered for gene therapy
Int Rev Cell Mol Biol. 2023;379:1-41. doi: 10.1016/bs.ircmb.2023.05.005. Epub 2023 Jul 1.ABSTRACTGene therapy has seen major progress in recent years. Viral vectors have made a significant contribution through efficient engineering for improved delivery and safety. A large variety of indications such as cancer, cardiovascular, metabolic, hematological, neurological, muscular, ophthalmological, infectious diseases, and immunodeficiency have been targeted. Viral vectors based on adenoviruses, adeno-associated viruses, herpes simplex viruses, retroviruses including lentiviruses, alphaviruses, flaviviruses, measles viruses, rh...
Source: Mol Biol Cell - August 4, 2023 Category: Molecular Biology Authors: Kenneth Lundstrom Source Type: research

Adenovirus as a Vector and Oncolytic Virus
Curr Issues Mol Biol. 2023 Jun 2;45(6):4826-4840. doi: 10.3390/cimb45060307.ABSTRACTAdenoviral vectors, both oncolytic viruses and gene delivery vectors, are among the earliest approved and commercialised vectors for gene therapy. Adenoviruses have high cytotoxicity and immunogenicity. Therefore, lentiviruses or adeno-associated viruses as viral vectors and herpes simplex virus as an oncolytic virus have recently drawn attention. Thus, adenoviral vectors are often considered relatively obsolete. However, their high cargo limit and transduction efficiency are significant advantages over newer viral vectors. This review prov...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Wataru Matsunaga Akinobu Gotoh Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13